T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27809856)

Published in J Hematol Oncol on November 03, 2016


Claudia Zelle-Rieser1, Shanmugapriya Thangavadivel1, Rainer Biedermann2, Andrea Brunner3, Patrizia Stoitzner4, Ella Willenbacher5, Richard Greil1,6,7, Karin Jöhrer8

Author Affiliations

1: Tyrolean Cancer Research Institute, Innrain 66, 6020, Innsbruck, Austria.
2: Department of Orthopedic Surgery, Medical University of Innsbruck, Anichstraße 35, Innsbruck, Austria.
3: Department of Pathology, Medical University of Innsbruck, Müllerstraße 44, Innsbruck, Austria.
4: Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Anichstraße 35, Innsbruck, Austria.
5: Department of Internal Medicine V, Medical University of Innsbruck, Anichstraße 35, Innsbruck, Austria.
6: Salzburg Cancer Research Institute (SCRI), Müllner Hauptstraße 48, 5020, Salzburg, Austria.
7: Third Medical Department at The Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, Salzburg, Austria.
8: Tyrolean Cancer Research Institute, Innrain 66, 6020, Innsbruck, Austria. Karin.Joehrer@tkfi.at.

Articles cited by this

Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04

Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity (2007) 12.98

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51

Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A (2004) 4.56

IL-7 enhances the survival and maintains the size of naive T cells. J Immunol (2001) 3.39

Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37

Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity (2012) 2.16

T-bet in disease. Nat Immunol (2011) 2.09

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09

CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology (2011) 2.03

Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol (2015) 1.79

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74

Dysfunctional T regulatory cells in multiple myeloma. Blood (2005) 1.72

Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol (2007) 1.69

Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 1.66

Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2011) 1.64

Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity (2014) 1.54

Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood (2001) 1.37

Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells. Front Immunol (2013) 1.34

Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence. Aging Dis (2011) 1.33

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol (2016) 1.28

Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res (2013) 1.22

Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog (2011) 1.17

Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia (2015) 1.17

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol (2016) 1.17

The impact of aging on memory T cell phenotype and function in the human bone marrow. J Leukoc Biol (2011) 1.16

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood (2001) 1.07

2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. J Exp Med (2014) 1.06

Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood (1997) 1.05

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol (1996) 1.02

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res (2015) 0.98

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol (2016) 0.92

Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology (2013) 0.91

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia (2015) 0.90

CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression. PLoS Pathog (2014) 0.90

CD8+/CD57 cells and apoptosis suppress T-cell functions in multiple myeloma. Br J Haematol (1998) 0.89

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer (2015) 0.88

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol (2015) 0.86

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J (2015) 0.84

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia (2016) 0.82

The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma (1998) 0.82

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy. Clin Cancer Res (2011) 0.80

Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma - an analysis from the Austrian Myeloma Registry. Leuk Lymphoma (2015) 0.78

Bone marrow T cells from the femur are similar to iliac crest derived cells in old age and represent a useful tool for studying the aged immune system. Immun Ageing (2013) 0.78

Multiple myeloma: altered CD4/CD8 ratio in bone marrow. Haematologica (1990) 0.76

Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy. Oncoimmunology (2015) 0.76